- Home
- CZNC vs CLLS Comparison
CZNC vs CLLS Comparison
Compare CZNC & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CZNC | CLLS |
|---|---|---|
| Founded | 1864 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 377.5M | 394.4M |
| IPO Year | 2009 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CZNC | CLLS |
|---|---|---|
| Price | $20.70 | $3.48 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $23.50 | $8.33 |
| AVG Volume (30 Days) | ★ 34.4K | 21.1K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.87% | N/A |
| EPS Growth | ★ 7.64 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.11 | N/A |
| Revenue Next Year | N/A | $0.98 |
| P/E Ratio | $1,057.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.02 | $1.33 |
| 52 Week High | $24.12 | $5.48 |
Technical Indicators
Market Signals| Indicator | CZNC | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 36.38 | 40.01 |
| Support Level | $19.91 | $3.40 |
| Resistance Level | $20.63 | $3.83 |
| Average True Range (ATR) | 0.51 | 0.20 |
| MACD | 0.05 | -0.04 |
| Stochastic Oscillator | 32.05 | 6.67 |
Price Performance
Historical ComparisonAbout CZNC Citizens & Northern Corp
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.